ALT - Altimmune Inc.

-

$undefined

N/A

(N/A)

Altimmune Inc. NasdaqGM:ALT Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic associated steatohepatitis. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.

Location: 910 Clopper Road, Gaithersburg, MD, 20878, United States | Website: https://altimmune.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

292.2M

Cash

149.8M

Avg Qtr Burn

-20.08M

Short % of Float

28.19%

Insider Ownership

0.76%

Institutional Own.

47.87%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Pemvidutide (ALT-801) (GLP-1R/GCGR) Details
metabolic dysfunction-associated steatohepatitis (MASH)

Big Mover™

Susp. Mover™

Phase 2b

Data readout

Pemvidutide (ALT-801) (GLP-1R/GCGR) Details
Non-alcoholic steatohepatitis , Non-Alcoholic Fatty Liver Disease, metabolic dysfunction-associated steatohepatitis

Phase 2b

Data readout

Phase 2

Data readout

Phase 2

Update

Phase 2

Initiation

Pemvidutide (ALT-801) (GLP-1R/GCGR) Details
Alcohol-Associated Liver Disease

Phase 2

Initiation

NasoShield (Vaccine) Details
Anthrax, Bacterial infection

Failed

Discontinued

HepTCell Details
Chronic hepatitis B

Failed

Discontinued

Failed

Discontinued

Failed

Discontinued

Failed

Discontinued